A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
暂无分享，去创建一个
Douglas B. Johnson | P. Ott | L. Hart | J. Infante | A. Pavlick | O. Hamid | J. Luke | A. Salama | J. Lutzky | C. Turner | R. Bagley | L. Spitler | C. L. Cowey | Joshua Zhang | T. Hawthorne | N. E. Rothschild | Yi He | A. Alizadeh | C. Cowey